Parp inhibitor sensitivity

Show results for

Unknown (558)
Genomics (116)
Transcriptomics (61)
Proteomics (24)
Other (8)
Metabolomics (1)

Organisms

Homo sapiens (86)
Andropogon gerardi (18)
Bacteria (18)
Canis lupus familiaris (18)
Cnidaria (18)
Cricetulus griseus (18)
Eukaryota (18)
Fasciola (18)
Hepatitis B virus (18)
Human betaherpesvirus 5 (18)
Madurella mycetomatis (18)
Mesocricetus auratus (18)
Miscanthus x giganteus (18)
Mus musculus (18)
Mycobacterium tuberculosis (18)
Orthoflavivirus (18)
Panicum virgatum (18)
Platyhelminthes (18)
Pseudomonas aeruginosa AES-1R (18)
Rattus norvegicus (18)
Rattus rattus (18)
Rhodococcus jostii RHA1 (18)
Saccharomyces cerevisiae (18)
Severe acute respiratory syndrome coronavirus 2 (18)
Shigella (18)
Sorghastrum nutans (18)
Streptococcus dysgalactiae subsp. equisimilis SK1249 (18)
Mus musculus (16)
Arabidopsis thaliana (1)
Danio rerio (1)

Organisms

Homo sapiens (59)
Mus musculus (11)
Danio rerio (1)

Repository

ENA (87)
geo (65)
biostudies-arrayexpress (23)
pride (18)
EGA (10)
iProX (3)
jPOST (2)
MassIVE (1)
MetaboLights (1)

Tissue

Cell culture (5)
Epithelial cell (5)
Permanent cell line cell (5)
Cell suspension culture (1)
Kidney (1)
Liver (1)
Melanocyte (1)
Skin (1)

Disease

Malignant neoplasm of ovary (3)
Lung adenocarcinoma (2)
Breast cancer (1)
Skin melanoma (1)

Technology Type

Mass Spectrometry (18)
Affinity purification coupled with mass spectrometry proteomics (8)
Shotgun proteomics (8)
Bottom-up proteomics (5)
Data-dependent acquisition (3)
Illumina HiSeq 2000 (2)
ILLUMINA, Illumina HiSeq 2500 (1)
Mass spectrometry assay (1)

Instrument Platform

Illumina HiSeq 4000 (3)
Axon GenePix 4000A scanning hardware (1)
Illumina HiSeq 2500 (1)
Illumina NovaSeq 6000 (1)
NextSeq 500 (1)
Q Exactive HF (1)
Liquid Chromatography MS - negative - hilic (1)
Liquid Chromatography MS - positive - hilic (1)

Publication Date

2025 (25)
2026 (16)
2023 (14)
2024 (14)
2022 (12)
2014 (7)
2011 (4)
2020 (3)
2016 (3)
2017 (3)
2015 (2)
2010 (2)
2018 (2)
2013 (1)
2012 (1)
2009 (1)
2008 (1)
2007 (1)
2019 (1)

First Public Date

2025 (24)
2026 (15)
2022 (10)
2023 (9)
2024 (8)
2020 (4)
2017 (4)
2014 (4)
2019 (3)
2015 (3)
2013 (2)
2018 (1)

Study type

Transcription profiling by array (14)
RNA-seq of coding RNA (5)
ChIP-seq (2)
ChIP-chip by tiling array (1)
DNA-seq (1)

Release Date

2025 (70)
2022 (63)
2020 (60)
2023 (59)
2021 (47)
2019 (45)
2018 (43)
2024 (40)
2017 (30)
2014 (28)
2016 (21)
2015 (18)
2013 (13)
2026 (11)
2012 (9)
2011 (9)
2010 (8)
2008 (3)
2007 (2)
2009 (1)

Lab affiliation

1State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, Peking University, Beijing, China 2Department of Biochemistry and Molecular Biology, School of Life Sciences, Peking University, Beijing, China, Peking University, Beijing 100871, China (2)
Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, 75390, TX, USA (2)
Center for Diagnostics, Section Mass Spectrometry and Protemics, University Medical Center Hamburg-Eppednorf, Hamburg, Germany (1)
Centre de recherche du CHU de Québec - Université Laval (1)
Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), INF280, 69120 Heidelberg, Germany (1)
Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), INF280, 69120 Heidelberg, Germany. (1)
Drug Discovery Moffitt Cancer Center Tampa, FL, USA (1)
Mayo Clinic (1)
Moffitt Cancer Center Tampa, FL, USA (1)
Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, DK-2200 Copenhagen, Denmark (1)
Proteomics program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark (1)
Stanford Cancer Institute, Stanford University (1)
State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, Peking University, Beijing, China 100871. (1)
The Institute of Cancer Research (1)
University of Oxford Sir William Dunn School of Pathology Oxford OX1 3RE, UK (1)
University of Science and Technology of China (1)

Previous page
1 / 77
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 77
Next page

Sort by:

Relevance

Page size

Targeting SLC1A5-mediated glutamine metabolism overcomes PARP inhibitor resistance in ovarian cancer

Poly(ADP-ribose) polymerase inhibitors (PARPi), such as olaparib, have significantly improved outcomes in ovarian cancer (OC); however, therapy resistance remains a major clinical challenge. Here, we showed that glutamine metabolism was upregulated in PARPi-resistant OC cells and identified the g...

2026-04-08 | MTBLS14072 | MetaboLights

PARP Inhibitor Sensitivity in BRCA-Proficient ovarian cancer cells is regulated by the MSH6–CHAF1A axis: 2. ADP-Ribosylation

Ovarian cancer is the leading cause of gynecologic cancer-related deaths, with high-grade serous ovarian cancer (HGSOC) being the most common and lethal subtype. While BRCA1/2 mutations are established biomarkers predicting sensitivity to PARP inhibitors (PARPis), a subset of patients with BRCA-prof...

ORGANISM(S): Homo sapiens (Human)

2026-08-21 | PXD067891 | Pride

PARP Inhibitor Sensitivity in BRCA-Proficient ovarian cancer cells is regulated by the MSH6–CHAF1A axis: 1. Chemical Proteomics

ORGANISM(S): Homo sapiens (Human)

2026-08-21 | PXD067882 | Pride

Ovarian cancer Msh6 Parp Chaf1a

MRE11 Deficiency Increases Sensitivity to Poly(ADP-ribose) Polymerase Inhibition in Microsatellite Unstable Colorectal Cancers.

We have performed bioinformatic approaches to identify the level of enrichment between gene expression profiles characterizing MSI tumors and gene changes induced in vitro by the PARP-1 inhibitor Phenanthridinone and others using the Connectivity Map tool. In a first step, we have anyzed the express...

ORGANISM(S): Homo sapiens

2011-04-07 | E-GEOD-26682 | biostudies-arrayexpress

MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells

PRJEB62092 | ENA

CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer

PRJNA1039833 | ENA

TET2 loss triggers ssDNA gap accumulation and heightened PARP inhibitor sensitivity

PRJNA1457529 | ENA

TET2 loss triggers ssDNA gap accumulation and heightened PARP inhibitor sensitivity

PRJNA1457530 | ENA

5hmC enhances PARP trapping and restores PARP inhibitor sensitivity in chemoresistant BRCA1/2-deficient cells.

Not available